Kevin Grogan

Kevin Grogan

Managing Editor

London, UK

Covering all aspects of the pharma industry and across all therapeutic areas, Kevin has interviewed pretty much all the leading figures in the sector. A regular attendee at financial and medical conferences (and moderating at some), he has also appeared on BBC television and radio, ITV and Channel 4 to discuss the industry. Fluent in Spanish, he previously worked as a journalist on rock/pop music publications, was chief sub editor at Catholic newspaper The Universe and contributed articles to the likes of The Independent and the Manchester Evening News on football.

Latest from Kevin Grogan

GSK Chief Optimistic About BD Despite Volatile Environment

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

Soriot Cautions Europe Amid More US Expansion

The AstraZeneca CEO again calls for rich European countries to pay more for new drugs because "a model where the US funds innovation in our industry for the entire world doesn't work."

AstraZeneca’s Truqap Trips Up In Prostate Cancer Study

The AKT inhibitor proves ineffective for metastatic castration-resistant disease in a Phase III trial.

UPDATED: Merck KGaA Seals SpringWorks Buy

The German group is paying $3.9bn to get hold of the US firm and its two approved products.

Sanofi Spends Big In US But Offers Crumbs Of Comfort For Europe

CFO François Roger tells Scrip the French drugmaker is flexible geographically on making investments but its spend in the US has risen regardless of the threat of tariffs.

Europe Should Pay Drug Prices More In Line With US, Two Pharma CEOs Argue

Sanofi's Paul Hudson and Novartis's Vas Narasimhan claim that while Europe is home to some of the most important biopharma companies in the world, its position is in jeopardy.